Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.

ABSTRACT:

SUBMITTER: Qualls D 

PROVIDER: S-EPMC10841916 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature